Interleukin-28B genotyping by melt-mismatch amplification mutation assay PCR analysis using single nucleotide polymorphisms rs12979860 and rs8099917, a useful tool for prediction of therapy response in hepatitis C patients

J Clin Microbiol. 2011 Jul;49(7):2706-10. doi: 10.1128/JCM.00877-11. Epub 2011 May 25.

Abstract

Several studies have identified associations between single nucleotide polymorphisms (SNPs) occurring near the interleukin-28B (IL-28B) gene and response to antiviral treatment among hepatitis C virus (HCV) patients. Here, we describe a reliable melt-mismatch amplification mutation assay (melt-MAMA) PCR-based genotyping method for IL-28B which can be used in the management of HCV patients, helping to better define the course of therapy.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antiviral Agents / administration & dosage*
  • Female
  • Genotype
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferons
  • Interleukins / genetics*
  • Male
  • Middle Aged
  • Mutation*
  • Polymerase Chain Reaction / methods*
  • Polymorphism, Single Nucleotide*
  • Prognosis
  • Transition Temperature*
  • Treatment Outcome

Substances

  • Antiviral Agents
  • interferon-lambda, human
  • Interleukins
  • Interferons